Editorial: mitigating primary nonresponse to infliximab—are we better equipped now?

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2036|47|3|434-435

ISSN: 0269-2813

Source: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 434-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract